Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
IMMUNOCOVID
1 other identifier
observational
300
1 country
1
Brief Summary
In January 2020, researchers isolated and sequenced in China from patients with severe atypical pneumonia a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread throughout the world. SARS-CoV-2 may trigger hyperstimulation of immune system with an autoinflammatory response but also the development of an autoimmune process. These autoimmune responses may also develop through the molecular mimicry between virus and human-self components. Multiple autoantibodies have been described in COVID-19 patients. Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator has been identified as a new autoantigen in antiphospholipid syndrome. ANXA2 has been identified as candidate autoantigen recognized by SARS patient sera. ANXA2 contributes also to pulmonary microvascular integrity. These data lead to identify anti-ANXA2 antibodies in COVID-19 patient sera and to know if the presence of these antibodies is associated with pulmonary injury or thrombosis in COVID-19 and represents a marker of severity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 15, 2022
CompletedStudy Start
First participant enrolled
February 15, 2022
CompletedFirst Posted
Study publicly available on registry
February 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2023
CompletedFebruary 8, 2023
February 1, 2023
1.5 years
February 15, 2022
February 7, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence of anti-ANXA2 antibodies in patients with COVID-19 infection
6 months
Eligibility Criteria
All patients hospitalized in Amiens University Hospital with COVID-19 infection
You may qualify if:
- years and older
- All patients hospitalized in Amiens University Hospital with COVID-19 infection
You may not qualify if:
- Autoimmune diseases
- Chronic viral infection by hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV)
- Immunosuppressive treatment
- Solid tumors
- Hematological malignancies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Amiens
Amiens, 80054, France
Biospecimen
blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 15, 2022
First Posted
February 16, 2022
Study Start
February 15, 2022
Primary Completion
August 1, 2023
Study Completion
August 1, 2023
Last Updated
February 8, 2023
Record last verified: 2023-02